125
Participants
Start Date
July 31, 2012
Primary Completion Date
January 31, 2015
Study Completion Date
February 11, 2015
Placebo
Sham treatment acting as control arm
Tetrodotoxin
Comparison of different dosages of Tetrodotoxin
Gettysburg Cancer Center, Gettysburg
Center for Cancer and Blood Disorders, Bethesda
Cancer Center of Middle Georgia, Dublin
Axcess Medical Research, Wellington
Medsol Clinical Research Center, Port Charlotte
Signal Point Clinical Research Center, Middletown
St. Louis Cancer Care, Bridgeton
Mercy Medical Research Institute, Springfield
Cancer Center of Kansas, Wichita
Institute of Pain Research, Oklahoma City
Jean Brown Research, Salt Lake City
New Mexico Oncology Hematology Consultants, Albuquerque
Global Research Management, Los Angeles
Innovative Clinical Research, Los Angeles
Alliance Research Centers, Laguna Hills
Lalita Pandit, Fountain Valley
Robert Moss, Fountain Valley
Pacific Cancer Care, Salinas
El Camino Cancer Center, Mountain View
Redwood Regional Medical Group, Santa Rosa
St. Vincent's Medical Center, Bridgeport
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
University of Texas Southwestern, Dallas
Collaborators (1)
Premier Research Group plc
UNKNOWN
Wex Pharmaceuticals Inc.
INDUSTRY